PALISADE BIO stockholders approved a potential reverse stock split, elected three directors, and ratified Baker Tilly US as its accounting firm.
DIH Holding US reported a 2.5% decline in fiscal 2025 revenue to $62.9 million and an increased net loss, alongside a 1-for-25 reverse stock split.
Beneficient reported a $65.1 million net loss in Q1 fiscal 2026, citing strategic moves like cost reductions, new capital transactions, and asset sales to strengthen its financial position.
Evofem Biosciences terminated its merger agreement with Aditxt after shareholders rejected the proposal, prompting the company to seek a national stock listing.
Ur-Energy filed a prospectus supplement to register common shares for exercise of 2023 warrants; no new warrants were issued.
VSEE HEALTH secured a $133,333.33 note from an institutional investor on October 20, 2025, while also terminating its Equity Purchase Agreement.